In the past decade, emerging therapeutic modalities like cell and gene therapies have opened up new treatment options for previously intractable diseases, changing the industry needs for primary tissues. While
Primary cells, such as those isolated from the bone marrow or peripheral blood, are important for a wide scope of research and clinical applications – from studying molecular mechanisms driving disease progression, to
Adoptive cell therapies (ACTs), which is a treatment based on transferring cells (most often immune cells) into a patient, have revolutionized the standard of care to treat a broad range
Isolated human primary cells are able to retain the morphological and functional characteristics of their tissue of origin, which makes them invaluable tools in life sciences to advance our understanding
T cells are the main effector cells of the adaptive immune system and can be distinguished from other white blood cells by the presence of a T-cell receptor (TCR) on
B cells are lymphocytes that are part of the adaptive humoral immune system and are best known for their ability to produce antigen-specific antibodies. B cells express B cell receptors
Welcome to the second installment of our FAQ blog series! Today, we are looking at differences between CD34+ cells isolated from different tissue sources to provide a better understanding of
While next generation cell-based treatments like CAR-T immunotherapies have been the source of much excitement and clinical investment in recent years, cellular therapies have a long, established history in the
Welcome to the first installment of the FAQ series here on the AllCells blog where we will answer some key questions relating to hematological tissue products. Today, we will unpack
With the FDA approvals of several cell therapy products (Kymriah® and Yescarta®) and many more cell therapies progressing towards clinical trials, sourcing high-quality cellular materials has become a critical determinant
Copyright ©
AllCells. All rights reserved.
